About this trial
Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) with propofol. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of this study is to assess the efficacy of the COMBO Endoscopy Oropharyngeal Airway in reducing the incidence of hypoxia in patients undergoing ERCP under sedation.
Eligibility criteria
Qualifiers
Age ≥18 years;
The ASA classification ranges from I to III.
Patients have signed the informed consent form.
Patients scheduled to undergo sedated ERCP examination;
Disqualifiers
Patients with coagulation disorders, tendency for oral/nasal bleeding, mucosal injury/occupying lesions, or difficult oropharyngeal airway insertion making airway management unfeasible;
Severe cardiac dysfunction (<4 METs);
Severe renal insufficiency (requiring preoperative dialysis);
Child-Pugh class C;
Trial design
Treatments tested in this trial
- The COMBO Endoscopy Oropharyngeal Airway